Three COVID-19 vaccines, developed by Bharat Biotech, Serum Institute of India and Pfizer, are under active consideration of India's drug regulator and there is hope that early licensure is......
Pfizer India has become the first pharmaceutical firm to seek from the Drugs Controller General of India an emergency use authorisation for its COVID-19 vaccine in the country, after its parent......
Prime Minister Narendra Modi will on Saturday visit the Pune-based Serum Institute of India (SII), which has partnered with global pharma giant AstraZeneca and the Oxford University for COVID-19......
If the advanced clinical trials of COVID-19 vaccine succeed, then an effective vaccination is likely to be available by the end of first quarter of 2021, Minister of State for Health Ashwini......
The central drug regulator has issued a show-cause notice to the Serum Institute of India (SII) for not informing it about pharma giant AstraZeneca pausing the clinical trials of the Oxford vaccine......
Even as private firms were busy stitching merger and partnership deals, the government also remained active during the year working on a separate policy to promote and strengthen domestic......
The Sensex ended 15 points lower at 28,163 after hitting life-time high of 28,282.85 and the Nifty ended down 5 points at 8,426 after touching an all-time high of 8,454.50. B enchmark share......
The recent fracas between Maruti Suzuki and its minority shareholders has blown the lid off the tension that has been steadily building between minority shareholders and listed multinational......
Global drugmakers have had a nauseous time in India's $14 billion market. Prices have dropped and valuable patents have been overruled as the authorities strive to make medicines affordable for the......
A sharp decline in India's current account deficit during the December quarter coupled with a sustained buying by foreign funds in the past few sessions fuelled the markets to all-time highs on......